TCGA-AR-A2LM-01A-11R-A180-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- TGF_BETA_SIGNALING+0.420
- HEDGEHOG_SIGNALING+0.370
- APICAL_JUNCTION+0.260
- WNT_BETA_CATENIN_SIGNALING+0.250
- ANGIOGENESIS+0.210
- NOTCH_SIGNALING+0.200
- TNFA_SIGNALING_VIA_NFKB+0.200
- KRAS_SIGNALING_UP+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- E2F_TARGETS-0.580
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V1-0.560
- MTORC1_SIGNALING-0.500
- G2M_CHECKPOINT-0.490
- INTERFERON_ALPHA_RESPONSE-0.460
- DNA_REPAIR-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- CHOLESTEROL_HOMEOSTASIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A1AL-01A-21R-A12P-07 | — | A | 0.935 |
| 2 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.928 |
| 3 | SRR8613708 | — | A | 0.917 |
| 4 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.910 |
| 5 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.906 |
| 6 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.904 |
| 7 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.901 |
| 8 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.896 |
| 9 | TCGA-BH-A0H3-01A-11R-A12P-07 | — | A | 0.893 |
| 10 | MBCProject_3896_T1_RNA | — | A | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.550 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |